Introduction The Surpass Evolve Flow Diverter (SE-FD) was launched in 2019 as a new generation FD of Surpass Streamline.
Aim of Study We aimed to assess and report the effectiveness and safety of SE-FD insertion for unruptured intracranial aneurysms at six-month and one-year follow-up.
Methods Between November 2019 and October 2021, a total of 106 patients with 108 aneurysms were treated with the FD at a single institution. Of these, SE-FD insertion was performed in 40 patients with 41 aneurysms. At six-month and one-year follow up, clinical and radiologic outcomes were retrospectively evaluated.
Results In present study, there were 12 male patients and 28 female patients, with a mean age of 59.1 years. Dissection or fusiform aneurysms was 46.3% (19/41). The maximal mean aneurysm diameter was 13.2 mm; and larger aneurysms, at least 15 mm, accounted for 34.1% (14/41) of cases. Among the 41 aneurysms, complex aneurysms (recurrent, thrombosed, or branch artery-incorporated) accounted for 41.5% (17/41). All procedures were successfully conducted with 7.3% (3/41) procedure-related complications. At one-year follow up (n = 40), neurologic morbidity was noted in two cases (5.0%; both mRS 1) without any mortality. At one-year follow-up (n = 41), radiologic outcomes were adequate occlusion in 33 aneurysms (80.5%) and complete occlusion in 29 aneurysms (70.7%). There was no retreatment in our cohort.
Conclusion SE-FD was safe and effective for the treatment of dissecting/fusiform or complex aneurysms at one-year follow-up. However, further study is needed to evaluate long-term results.
Disclosure of Interest Nothing to disclose
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.